Use of aerosolized levofloxacin for treating cystic fibrosis
First Claim
Patent Images
1. A method for treating a pulmonary infection in a human having cystic fibrosis, wherein the pulmonary infection comprises Pseudomonas aeruginosa, the method comprising:
- administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human having cystic fibrosis to treat the Pseudomonas aeruginosa pulmonary infection;
wherein the levofloxacin is in an aerosol of a solution comprising levofloxacin at a concentration from about 90 mg/ml to about 110 mg/ml, a magnesium cation at a concentration from about 175 mM to about 225 mM, wherein the solution has a pH from about 5 to about 7, and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.
6 Assignments
0 Petitions
Accused Products
Abstract
Methods for treating cystic fibrosis. The method includes administering to a human in need thereof an aerosol solution comprising levofloxacin or ofloxacin and a divalent or trivalent cation. More particularly, the method includes administering the aerosol solution to a human having a pulmonary infection comprising P. aeruginosa.
231 Citations
24 Claims
-
1. A method for treating a pulmonary infection in a human having cystic fibrosis, wherein the pulmonary infection comprises Pseudomonas aeruginosa, the method comprising:
-
administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human having cystic fibrosis to treat the Pseudomonas aeruginosa pulmonary infection; wherein the levofloxacin is in an aerosol of a solution comprising levofloxacin at a concentration from about 90 mg/ml to about 110 mg/ml, a magnesium cation at a concentration from about 175 mM to about 225 mM, wherein the solution has a pH from about 5 to about 7, and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method for treating a pulmonary Pseudomonas aeruginosa infection in a human in need thereof, wherein the human has cystic fibrosis;
- the method comprising;
administering via inhalation 240 mg of levofloxacin twice daily for 28 days to the human having cystic fibrosis to treat the Pseudomonas aeruginosa pulmonary infection; wherein the levofloxacin is present in an aerosol of a solution comprising about 100 mg/ml of levofloxacin and about 200 mM of magnesium chloride, and wherein the solution has a pH from about 5 to about 7, and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19)
- the method comprising;
-
20. A method for treating a pulmonary Pseudomonas aeruginosa infection in a human in need thereof, wherein the human has cystic fibrosis;
- the method comprising;
administering via inhalation 240 mg of levofloxacin twice daily for 28 days, and thereafter discontinuing administration of the levofloxacin for 28 days, to treat the Pseudomonas aeruginosa pulmonary infection in the human having cystic fibrosis; wherein the levofloxacin is present in an aerosol of a solution comprising about 90 mg/ml to about 110 mg/ml of levofloxacin and about 175 mM to about 225 mM of magnesium chloride, and wherein the solution has a pH from about 5 to about 7, and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. - View Dependent Claims (21, 22, 23, 24)
- the method comprising;
Specification